When was Qilu Pharmaceutical Group founded?

Qilu Pharmaceutical Group was founded in 1958.

Where is Qilu Pharmaceutical Group located?

Qilu Pharmaceutical Group is headquartered in Jinan, China.

Who is the current CEO of Qilu Pharmaceutical Group?

Xiayang Qiu of Qilu Pharmaceutical Group. They have also founded 1 company.

How many employees does Qilu Pharmaceutical Group have?

As of May 31, 2026, the latest employee count at Qilu Pharmaceutical Group is 246.

Is Qilu Pharmaceutical Group a funded company?

Qilu Pharmaceutical Group is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Qilu Pharmaceutical Group rank among its competitors?

Qilu Pharmaceutical Group ranks 11th amongst 972 active competitors, of which 38 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Enaltec Labs, which secured $1.33M in Jan, 2022.

Who are the top competitors of Qilu Pharmaceutical Group?

Qilu Pharmaceutical Group's top competitors include Symbiotec, Neuland and Hikal. Among them, Enaltec Labs secured the most recent funding round in January, 2022.

Qilu Pharmaceutical Group - 2026 Company Profile, Team, Funding & Competitors

Qilu Pharmaceutical Group is a funded company based in Jinan (China), founded in 1958 by Xiayang Qiu. It operates as a Developer and manufacturer of APIs and intermediates. The company has 972 active competitors, including 38 funded and 149 that have exited. Its top competitors include companies like Symbiotec, Neuland and Hikal.

Company Details

Qilu Pharmaceutical develops and manufactures APIs and intermediates (sterile and non-sterile). The products are of various therapeutic categories including oncology, cardiovascular, cerebrovascular, antiinfective, psychiatric, and ophthalmic diseases. They export their products to Australia, North America, Japan, and U.K.

Website: www.qilu-pharma.com
Social
Email ID: *****@qilu-pharma.com
Phone Number: +86 **********

Key Metrics

Founded Year

1958

Location

Jinan, China

Stage

Funding Raised

Investors

Yijing Capital

Ranked

11^th among 972 active competitors

Employee Count

246 as on May 31, 2026

Investment & Acquisitions

Arbutus Bio & 1 more

Similar Companies

Symbiotec & 1236 more

View Qilu Pharmaceutical Group's full profile

Qilu Pharmaceutical Group is a funded company. Qilu Pharmaceutical Group has 1 institutional investor.

View details of Qilu Pharmaceutical Group's funding rounds and investors

The founders of Qilu Pharmaceutical Group is Xiayang Qiu. Xiayang Qiu is the CEO of Qilu Pharmaceutical Group.

Here are the details of Qilu Pharmaceutical Group's key team members:

Xiayang Qiu: Founder & CEO of Qilu Pharmaceutical Group.

View details of Qilu Pharmaceutical Group's Founder profiles and Board Members

Qilu Pharmaceutical Group's employee count trend

Qilu Pharmaceutical Group has 246 employees as of May 26. Here is Qilu Pharmaceutical Group's employee count trend over the years:

Employee count trend for Qilu Pharmaceutical Group

Uncover Qilu Pharmaceutical Group's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Qilu Pharmaceutical Group include Symbiotec, Neuland and Hikal. Here is the list of Top 10 competitors of Qilu Pharmaceutical Group, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Symbiotec 2002, Indore (India), Acquired	Manufacturer of non sterile steroid hormone based APIs and intermediates	$61.1M	Franklin Templeton Investments, Actis & 21 others	63/100
2nd	Neuland 1984, Hyderabad (India), Public	Manufacturer of active pharmaceutical ingredients (APIs) and peptides	-	InvAscent, India Capital Growth & 1 others	58/100
3rd	Hikal 1988, Mumbai (India), Public	Traditional company offering contract research, custom synthesis & custom manufacturing of APIs and intermediates	-	IFC	57/100
4th	Beijing Biostar Technologies 2002, Beijing (China), Public	Developer and manufacturer of APIs, intermediates, & biochemical reagents	$135M	cdkjfw.cn, SDIC Venture Capital Management ... & 9 others	55/100
5th	IDT Australia Limited 1975, Boronia (Australia), Public	Providing cannabis product development and manufacturing services from API	$6M	CVC, I'Rom Group	54/100
6th	Embio 1986, Mumbai (India), Early Stage	Contract research and manufacturing company engaged in APIs and chiral intermediates	$292K	UTI, GURU NARAYAN FINCAP & 25 others	53/100
7th	SMS LifeSciences 2006, Hyderabad (India), Public	Manufacturer of Active Pharmaceutical Ingredients (API) and intermediate	-	-	53/100
8th	ST PHARM 2008, Siheung si (South Korea), Public	CDMO providing oligonucleotide, mRNA, and small molecule services	-	Shinhan Venture Investment, E&Investment & 1 others	53/100
9th	Sms Pharmaceuticals 1990, Hyderabad (India), Public	Traditional pharmaceutical company manufacturing active pharmaceutical ingredients (API)	-	-	52/100
10th	Enaltec Labs 2006, Mumbai (India), Acquired	Non-oncology API developer and manufacturer	$8.56M	InvAscent, Medtech Global & 7 others	52/100
11th	Qilu Pharmaceutical Group 1958, Jinan (China), Funding Raised	Developer and manufacturer of APIs and intermediates	-	Yijing Capital	51/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Qilu Pharmaceutical Group's competitors? Click here to see the top ones

Qilu Pharmaceutical Group has made 2 investments in Arbutus Bio and Regor. Qilu Pharmaceutical Group has not made any acquisitions as of now.

Media has covered Qilu Pharmaceutical Group for a total of 5 events in the last 1 year, 2 of them have been about company updates and 2 about partnerships.